China Pharmaceutical Market and Healthcare Industry Forecast and Analysis Report 2021-2025 apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Glenmark s Ryaltris® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
News provided by
Share this article
Share this article
The launch will ensure much-needed access to a novel fixed-dose combination nasal spray for this chronic condition
This marks Glenmark s first innovative product approval in the European Union
MUMBAI, India, April 26, 2021 /PRNewswire/ Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris
Glenmark s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Glenmark Pharmaceuticals rose 1.11% to Rs 565.25 after the company s Ryaltris nasal spray received an approval in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age.
The company is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union.
Ryaltris (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), will shortly be available in Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, and the UK.
Glenmark will commercialise Ryaltris on its own in select markets. In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark in 2020.
Glenmarks Ryaltris®- innovative single nasal spray, ready to market in Russia
MUMBAI, India, Feb. 22, 2021 /PRNewswire/ Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S A, received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris® Nasal Spray - a novel fixed-dose combination nasal spray.
This paves the way for commercialization of Ryaltris® in Russia which is expected to be made available to patients in the country in Q1 FY 2021-22.
Ryaltris® (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg) is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. Ryaltris® relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.